2020
Reliable prediction of survival in advanced-stage hepatocellular carcinoma treated with sorafenib: comparing 1D and 3D quantitative tumor response criteria on MRI
Doemel LA, Chapiro J, Laage Gaupp F, Savic LJ, Kucukkaya AS, Petukhova A, Tefera J, Zeevi T, Lin M, Schlachter T, Jaffe A, Strazzabosco M, Patel T, Stein SM. Reliable prediction of survival in advanced-stage hepatocellular carcinoma treated with sorafenib: comparing 1D and 3D quantitative tumor response criteria on MRI. European Radiology 2020, 31: 2737-2746. PMID: 33123796, PMCID: PMC8043967, DOI: 10.1007/s00330-020-07381-9.Peer-Reviewed Original ResearchConceptsTumor response criteriaOverall survivalAdvanced-stage HCCDisease progressionSorafenib therapyDisease controlResponse criteriaCox proportional hazards regression modelAdvanced-stage hepatocellular carcinomaProportional hazards regression modelsDCE-MRIInitiation of sorafenibTumor response analysisMultivariable Cox regressionIndependent risk factorMethodsThis retrospective analysisIndependent prognostic factorInitiation of treatmentKaplan-Meier analysisKaplan-Meier curvesHazards regression modelsLog-rank testStratification of patientsTotal tumor volumeArterial phase MRI
2017
Diagnostic value of dynamic contrast-enhanced CT with perfusion imaging in the quantitative assessment of tumor response to sorafenib in patients with advanced hepatocellular carcinoma: A feasibility study
Ippolito D, Querques G, Okolicsanyi S, Franzesi CT, Strazzabosco M, Sironi S. Diagnostic value of dynamic contrast-enhanced CT with perfusion imaging in the quantitative assessment of tumor response to sorafenib in patients with advanced hepatocellular carcinoma: A feasibility study. European Journal Of Radiology 2017, 90: 34-41. PMID: 28583645, DOI: 10.1016/j.ejrad.2017.02.027.Peer-Reviewed Original ResearchConceptsHepatic perfusion indexAdvanced hepatocellular carcinomaArterial perfusionHepatic perfusionHepatocellular carcinomaTarget lesionsHCC lesionsBlood volumeCirrhotic parenchymaPerfusion valuesTarget liver lesionsFollow-up scanSelection of patientsNon-responder groupDynamic contrast-enhanced CTContrast-enhanced CTAnti-angiogenic therapyPerfusion CT measurementsDedicated perfusion softwareStable diseaseSorafenib administrationPartial responseComplete responsePortal perfusionHemodynamic changes
2012
Cyclic AMP/PKA‐dependent paradoxical activation of Raf/MEK/ERK signaling in polycystin‐2 defective mice treated with sorafenib
Spirli C, Morell CM, Locatelli L, Okolicsanyi S, Ferrero C, Kim AK, Fabris L, Fiorotto R, Strazzabosco M. Cyclic AMP/PKA‐dependent paradoxical activation of Raf/MEK/ERK signaling in polycystin‐2 defective mice treated with sorafenib. Hepatology 2012, 56: 2363-2374. PMID: 22653837, PMCID: PMC3460040, DOI: 10.1002/hep.25872.Peer-Reviewed Original ResearchMeSH KeywordsAnimalsAntineoplastic Agents, HormonalBenzenesulfonatesBile DuctsCaspase 3Cell ProliferationCells, CulturedCyclic AMP-Dependent Protein KinasesCystsDrug Therapy, CombinationEpithelial CellsKi-67 AntigenLiver DiseasesMAP Kinase Signaling SystemMiceMice, KnockoutNiacinamideOctreotidePhenylurea CompoundsPhosphorylationProtein Kinase InhibitorsProto-Oncogene Proteins B-rafProto-Oncogene Proteins c-rafPyridinesSorafenibTRPP Cation ChannelsConceptsRaf-1Cell proliferationB-RafPhosphorylated ERKRaf kinase activitySignal-regulated kinase 1/2 pathwayRAF inhibitorsCyclic adenosine monophosphateRaf/MEK/ERKCyst growthDefective miceKinase 1/2 pathwayParadoxical activationCAMP/PKAMEK/ERKPolycystin-2Kinase AKinase activityWT cellsDependent activationERK1/2 phosphorylationInhibitor 14Epithelial cellsAdenosine monophosphateERK